The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study
El-Shitany, Nagla A; Bagher, Amina M; Binmahfouz, Lenah Saeed; Eid, Basma G; Almukadi, Haifa; Badr-Eldin, Shaimaa M; Mohammedsaleh, Zuhair M; Saleh, Fayez M; Almuhayawi, Mohammed S; Alghamdi, Samar A; Arab, Rana A; Harakeh, Steve; Alghamdi, Badrah S; elhamamsy, manal; Ali, Soad A.;
Abstract
Like other vaccines, Pfizer BioNTech's COVID-19 vaccine efficacy against SARS-CoV-2 virus infections begins to decline within a few months after the 2nd dose. On August 12, 2021, the FDA allowed additional Pfizer BioNTch's COVID-19 vaccine dose (3rd or booster dose) for individuals with weakened immunity. This study aimed to evaluate the short-term adverse reactions (ADRs) of the 2nd and the 3rd doses of the Pfizer BioNTech COVID-19 vaccine.
Other data
| Title | The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study | Authors | El-Shitany, Nagla A; Bagher, Amina M; Binmahfouz, Lenah Saeed; Eid, Basma G; Almukadi, Haifa; Badr-Eldin, Shaimaa M; Mohammedsaleh, Zuhair M; Saleh, Fayez M; Almuhayawi, Mohammed S; Alghamdi, Samar A; Arab, Rana A; Harakeh, Steve; Alghamdi, Badrah S; elhamamsy, manal ; Ali, Soad A. | Keywords | Pfizer-BioNTech COVID-19 vaccine; adverse drug reactions; booster dose; fatigue; injection site pain; online questionnaire; second dose | Issue Date | 2022 | Journal | International journal of general medicine | ISSN | 1178-7074 | DOI | 10.2147/IJGM.S376316 | PubMed ID | 36051568 | Scopus ID | 2-s2.0-85136415391 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.